3 New Strong Buy Ratings from Top-Rated Analysts: 05/01/2026
Using our popular Zen Ratings + Top Analysts feature, we sourced 3 stocks with excellent quant ratings and Smart Money support:
- Gilead Sciences (GILD) — HIV breakthrough and Arcellx deal fuel upside
- Amneal Pharmaceuticals (AMRX) — Biosimilars boom drives 339% EPS growth
- Levi Strauss (LEVI) — DTC transformation delivers double-digit revenue growth
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
10 AI Infrastructure Stocks to Watch
Free report reveals 10 publicly traded companies positioned across key layers of the AI ecosystem, from chip fabrication and custom silicon to data storage, connectivity, and cooling solutions. Plus insight into the major risks that could impact the AI infrastructure trade, including valuation concerns, industry cycles, geopolitical challenges, and execution risks.
1. Amneal Pharmaceuticals Inc (NASDAQ: AMRX)
Amneal Pharmaceuticals is emerging as a powerhouse in biosimilars scale opportunities, with strong preliminary Q1 results and a game-changing Kashiv BioSciences acquisition igniting analyst enthusiasm. Now ranked #1 in the Pharmaceutical industry, this generic and specialty drug manufacturer is positioned for serious upside.
Zen Rating: Strong Buy (A) — see full analysis
Recent Price: $12.79 — get current quote
Max 1-year forecast: $19.00
Why we're watching:
- Analyst support: AMRX enjoys unanimous bullish sentiment with 4 out of 4 analysts rating the stock Strong Buy. See the ratings
- For example, UBS researcher Ashwani Verma (a top 14% rated analyst) recently initiated coverage with a Strong Buy rating and $19 price target, representing 49% upside potential, highlighting the company's biosimilar pipeline and anticipated 2026-2027 upside from biosimilars scale.
- AMRX also enjoys strong support from our Editor-in-Chief Steve Reitmeister, whose recent video showcases the stock’s strengths. Watch it here
- Great growth: The company's earnings growth of 128.71% significantly outpaces both the industry average of 19.82% and market average of 72.91%, with EPS forecasted to grow from $0.23 to $1.01 over the next year—a remarkable 339% increase.
- Industry ranking context: AMRX is currently the #1 highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of A.
- Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — AMRX is in the top echelon of stocks we track.
- Component Grades: Outstanding performance in Growth (A) and Sentiment (A) grades, reflecting strong analyst conviction and impressive earnings expansion potential, complemented by a solid B grade in Value. (See all 7 Zen Component Grades here)
2. Levi Strauss & Co (NYSE: LEVI)
Levi Strauss, the iconic denim brand, is pulling off a stunning transformation into a DTC-first lifestyle powerhouse — and the numbers prove it. Q1 2026 direct-to-consumer revenues surged 16% year-over-year and now account for more than half of total revenue, with heritage demand and sharp operational focus fueling the fastest, most consistent growth in the company's history.
Zen Rating: Strong Buy (A) — see full analysis
Recent Price: $21.86 — get current quote
Max 1-year forecast: $34.00
Why we're watching:
- Analyst support: Strong consensus with 2 Strong Buy ratings and 3 Buy ratings from 5 analysts covering the stock, with zero Hold, Sell, or Strong Sell ratings. See the ratings
- For example, UBS researcher Jay Sole (a top 6% rated analyst) recently raised his price target to $34 following Q1 earnings, noting the company is "undertaking a transformation into a global, multi-channel, lifestyle brand for both men and women" that will support mid-single-digit revenue growth with mid-teens margins over time.
- Recent catalysts: Q1 2026 earnings showcased exceptional execution with EPS of $0.42 beating estimates by 13.51% and revenue of $1.74B exceeding expectations by 5.45%, both growing double-digits year-over-year as the DTC transformation gains momentum.
- Industry ranking context: LEVI is currently the #1 highest-rated stock in the Apparel Manufacturing industry, which has an Industry Rating of A.
- Zen Rating highlights: As an A or Strong Buy rated stock, LEVI ranks in the top 5% of stocks we track based on a 115-factor evaluation of factors that have historically driven long-term stock growth.
- Component Grades: Well-rounded performance with A grade in Sentiment reflecting strong analyst confidence, B grades in Value, Growth, Safety, and Financials, demonstrating solid fundamentals across the board. (See all 7 Zen Component Grades here)
3. Gilead Sciences Inc (NASDAQ: GILD)
Gilead Sciences is riding powerful momentum after the FDA granted priority review to its once-daily HIV treatment combining bictegravir and lenacapavir, while its newly completed Arcellx acquisition sets the stage for anito-cel's commercial launch. Ranked #1 in the General Drug Manufacturer industry, this biopharmaceutical leader continues delivering standout execution across its HIV and oncology franchises.
Zen Rating: Strong Buy (A) — see full analysis
Recent Price: $128.00 — get current quote
Max 1-year forecast: $180.00
Why we're watching:
- Analyst support: Strong Wall Street backing with 9 Strong Buy ratings, 2 Buy ratings, and 2 Hold ratings out of 13 analysts covering the stock. See the ratings
- For example, Needham researcher Joseph Stringer (a top 1% rated analyst) recently reiterated his Buy rating with a $170 price target following the company's strategic portfolio expansion. His target suggests over 30% potential upside in the coming year.
- Industry ranking context: GILD is currently the #1 highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A.
- Zen Rating highlights: GILD earns an overall Zen Rating of A, putting it in a class of stocks that have historically returned over 30% annually to investors.
- Component Grades: The stock excels with A grades in Value and Financials, indicating strong fundamentals and attractive valuation metrics, while maintaining a B grade in Safety and Artificial Intelligence exposure. (See all 7 Zen Component Grades here)
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.